Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018

'PRESS RELEASE'

NCT03582826
ClinicalTrials.gov

MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production
& PATM

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person

NO LONGER RECRUITING

Participation info : LINK English

MEBO Map Testing & Meetups


Full details : https://goo.gl/TMw8xu
want listed ? contact map@meboresearch.org

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

Metabolomic Profiling Study
NCT02683876

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned


Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
EURORDIS and
NORD Member Organization
See RareConnect
BannerFans.com
RESEARCH DETAILS

DONATIONS THRU 31-NOV-2016:
£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14

MEBO UK PAYPAL FOR TRINZYME

********
MEBO US PAYPAL FOR TRINZYME

Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers


Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Monday, November 19, 2018

Orphan Drug Act Resolution Introduced in Congress


As a Member Organization of the National Organization for Rare Disorders (NORD), MEBO is in a position to unite with attorneys and legislators to support the passing of resolutions, such as the Orphan Drug Act Resolution mentioned in the NORD policy alert below.

H.Res.1154 was introduced in Congress by Senator Hatch and Representatives Lance and Butterfield, affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases. For more information on the Resolution, here. Additionally, for more general information on the ODA, check out NORD's new one-pager here

The Orphan Drug Act has the potential of increasing the possibility of researchers for our community to obtain research grants to develop or designate existing therapeutics for conditions suffered by members of the MEBO Community around the world. Therefore, all sufferers in the United States are asked to write to their Senators and Representatives asking them to "demonstrate your support for the ODA by cosponsoring H.Res 1154 and S.Res 690" which,

(1) applauds the tremendous growth in research and development into new therapies for rare diseases and the resulting number of FDA-approved therapies for people living with rare diseases;
(2) recognizes that significant research and development efforts and related investments are needed to develop therapies to treat and cure the thousands of rare diseases for which no treatment options are currently available; and
(3) affirms the need to continue supporting public and encouraging private investment in research and development of new treatments for rare diseases.



María
María de la Torre
Founder and Executive Director

A Public Charity
maria.delatorre@meboresearch.com
www.meboresearch.org
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)




SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.


get New Posts by EMAIL : Enter your email address :






A EURORDIS and NORD Member Organization

0 comments:

Post a Comment